文献速递泌尿生殖与妇科肿瘤放疗

ONE SHOT——局限性前列腺癌单次放疗:单臂多中心I/II期试验18个月结果

ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial.
PubMed 文献 · Radiother Oncol · 2024-02-24

这项前瞻性、多中心、单臂I/II期研究评估了低危和中危局限性前列腺癌患者接受单次19 Gy尿道保护立体定向体部放疗的早期安全性和疗效。45例患者中43例按方案接受单次照射,34例随访至少18个月;泌尿生殖毒性在第5天最明显后恢复,18个月时出现12%的2级症状 flare,3例(7%)生化失败。作者结论认为该方案可行且毒性可接受,但需更长期随访评估远期不良反应和疾病控制疗效。

要点

  • 单次19 Gy尿道保护SBRT在低中危局限性前列腺癌中可行,急性泌尿生殖毒性多在第12周恢复至基线。
  • 第18个月出现12%的2级泌尿生殖症状 flare,1例患者在12个月时发生3级直肠炎。
  • 中位随访26个月观察到3例(7%)生化失败,分别在第17、21和30个月。

核心结论

  • 作者结论认为,19 Gy单次尿道保护SBRT可行且毒性率可接受,症状多在第12周恢复至基线,并在第12至18个月间出现症状 flare。
  • 作者指出需要更长期随访以评估潜在的远期不良反应和疾病控制疗效。

研究设计与样本

  • 前瞻性、多中心、单臂I/II期研究,招募无显著移行区肿瘤的低危和中危局限性前列腺癌患者。
  • 单次19 Gy照射前列腺,尿道剂量降低至17 Gy,使用前列腺内电磁传感器监测分次内运动并对超过3 mm的位移进行分次内校正。
  • 2017年至2022年间在5个中心招募45例患者,其中43例无方案偏差接受单次照射,34例随访至少18个月。

主要发现

  • 最严重的泌尿生殖毒性出现在SBRT后第5天,1级和2级分别为42.5%和20%,第12周和第6个月恢复至基线(2级<3%),第18个月出现12%的2级 flare。
  • 急性期胃肠道毒性轻微,无≥2级事件(第6个月1级为12%);1例患者在第12个月发生3级直肠炎,第18个月2级毒性<3%。
  • 平均泌尿生殖和胃肠道困扰评分在第5天下降,第6个月完全恢复,第12至18个月间出现 flare。
  • 平均PSA从6.2 ng/ml降至第18个月的1.2 ng/ml和第24个月的0.7 ng/ml;中位随访26个月,观察到3例(7%)生化失败,分别在第17、21和30个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要更长期随访以评估潜在的远期不良反应和疾病控制疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess in a prospective, multicenter, single-arm phase I/II study the early safety and efficacy profile of single fraction urethra-sparing stereotactic body radiotherapy (SBRT) for men with localized prostate cancer. MATERIAL AND METHODS: Patients with low- and intermediate-risk localized prostate cancer without significant tumor in the transitional zone were recruited. A single-fraction of 19 Gy was delivered to the prostate, with 17 Gy dose-reduction to the urethra. Intrafraction motion was monitored using intraprostatic electromagnetic transponders with intra-fraction correction of displacements exceeding 3 mm. Genitourinary (GU), gastrointestinal (GI), and sexual toxicity during the first 18 months were evaluated using the CTCAE v4.0 grading scale. Quality of life was assessed using the International Prostate Symptom Score, the Expanded Prostate Cancer Index composite 26 score, and the International Index of Erectile Function score. RESULTS: Among the 45 patients recruited in 5 centers between 2017 and 2022, 43 received the single fraction without protocol deviations, and 34 had a minimal follow-up of 18 months. The worst GU toxicity was observed at day-5 after SBRT (42.5 % and 20 % with grade 1 and 2, respectively), returning to baseline at week-12 and month-6 (<3% with grade 2), with a 12 % grade 2 flare at month 18. Gl toxicity was mild in the acute phase, with no grade ≥ 2 events (12 % grade 1 at month 6). Grade-3 proctitis was observed in one patient at month 12, with < 3 % grade 2 toxicity at month 18. Mean GU and GI bother scores showed a decline at day 5, a complete recovery at month 6, and a flare between month 12 and 18. Mean PSA dropped from 6.2 ng/ml to 1.2 ng/ml at month 18 and 0.7 ng/ml at month 24. After a median follow-up time of 26 months, 3 biochemical failures (7 %) were observed at month 17, 21 and 30. CONCLUSIONS: In this multicenter phase I/II trial, we demonstrated that a 19 Gy single-fraction urethra-sparing SBRT is feasible and associated with an acceptable toxicity rate, mostly returning to the baseline at week-12 and with a symptoms flare between months 12 and 18. Longer follow-up is needed to assess the potential long-term adverse effects and the disease control efficacy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zilli T, Franzese C, Guckenberger M, et al. ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial. Radiother Oncol. 2024. PMID: 38403022. doi:10.1016/j.radonc.2024.110181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。